Fatigue News and Research

RSS

Pfizer’s Prevenar 13 gets US approval for adults

Health authorities of United States have approved the expansion of Pfizer Inc's Prevnar vaccine for use in adults 50 and older to fight pneumonia, meningitis and other diseases cause by pneumococcus bacteria. The vaccine, which had been approved for children in the United States, is already one of Pfizer's biggest brands and an expanded population of adults could generate more than $1.5 billion in annual sales.

2 Jan 2012

FDA approves Prevnar 13 pneumococcal conjugate vaccine for adults 50 and older

Prevnar 13, a pneumococcal 13-valent conjugate vaccine, was approved today by the U.S. Food and Drug Administration for people ages 50 years and older to prevent pneumonia and invasive disease caused by the bacterium, Streptococcus pneumoniae.

31 Dec 2011

Patented ribose for food, beverage and supplement applications

Since 2008, the sales of ribose as an energy supplement increased by over 85%. This in conjunction with $9 billion sales of functional energy drinks in 2011 suggests that demand has never been higher for ingredients with a wide array of applications in functional food and beverage industries. Enter Bioenergy Ribose – the Superior Energy Ingredient.

31 Dec 2011

Study linking chronic fatigue syndrome with virus infection retracted

The study published in the journal Science in October 2009, which found an association between the illness and a mouse leukemia retrovirus known as XMRV, was retracted last week by the editors of the journal.

28 Dec 2011

Scientific journal retracts study that linked mouse virus to human chronic fatigue syndrome

Editors at the journal Science have retracted a study that linked a virus in mice to chronic fatigue syndrome in humans after the Cleveland Clinic said some data came from a contaminated lab.

23 Dec 2011

Top-line results from Noven's LDMP Phase 3 clinical study on menopausal VMS

Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced top-line results from the first of two planned Phase 3 clinical studies evaluating low-dose mesylate salt of paroxetine (LDMP, formerly referred to as Mesafem) for the treatment of vasomotor symptoms (VMS) associated with menopause.

23 Dec 2011

Low-gluten beers can cause symptoms in patients with celiac disease

Beer tested in a new study, including some brands labeled "low-gluten," contains levels of hordein, the form of gluten present in barley, that could cause symptoms in patients with celiac disease (CD), the autoimmune condition treated with a life-long gluten-free diet, scientists are reporting.

22 Dec 2011

Survey: 40% of police officers have sleep disorders

A survey of police officers indicated that about 40 percent have a sleep disorder, which was associated with an increased risk of adverse health, safety and performance outcomes, according to a study in the December 21 issue of JAMA.

21 Dec 2011

Takeda receives FDA approval for EDARBYCLOR to treat hypertension

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., announced that the U.S. Food and Drug Administration (FDA) approved EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the treatment of hypertension to lower blood pressure in adults.

21 Dec 2011

Patients need less blood after surgery than is widely thought

Patients need less blood after surgery than is widely thought. A new study comparing two plans for giving blood transfusions following surgery showed no ill effects from postponing transfusion until patients develop signs of anemia or their hemoglobin concentration falls below 8 g/dL.

16 Dec 2011

Researchers identify second oldest human disease mutation

A new study has identified a gene mutation that researchers estimate dates back to 11,600 B.C., making it the second oldest human disease mutation yet discovered.

16 Dec 2011

Lockheed Martin, Johns Hopkins partner to create safer and more efficient ICU model

The Armstrong Institute for Patient Safety and Quality of Johns Hopkins Medicine is collaborating with the Lockheed Martin Corporation, a global security and technology company, to create a safer and more efficient hospital intensive care unit (ICU) model.

15 Dec 2011

Five tips to identify unstable individuals during holidays

While it is true that the suicide rate at the holidays is actually lower than at other times of the year, the holidays can be a very lonely time for those with nowhere to go and no one to turn to. As a result, the hospital emergency department sees an increase in visits from people who have engaged in potentially self-destructive or depressive behavior.

15 Dec 2011

Chronic fatigue syndrome may be reason behind many school absenteeism: Study

According to a new study one in 100 secondary school pupils could be missing classes because of chronic fatigue syndrome, also known as Myalgic Encephalomyelitis (ME). A study following 2,855 pupils at three schools, published in the online journal BMJ Open, found 28 missed school with chronic fatigue syndrome.

14 Dec 2011

CTI, Chroma announce final results from tosedostat phase II study on AML

Cell Therapeutics, Inc. and Chroma Therapeutics Ltd. announced that final results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) were presented by Jorge Cortes, M.D. of the University of Texas M.D. Anderson Cancer Center during the Acute Myeloid Leukemia - Therapy, excluding Transplantation: Clinical Studies session at the American Society of Hematology Annual Meeting.

14 Dec 2011

Scientists identify gene mutation behind Waldenstrom's macroglobulinemia

Scientists at Dana-Farber Cancer Institute have identified a gene mutation that underlies the vast majority of cases of Waldenstrom's macroglobulinemia, a rare form of lymphoma that has eluded all previous efforts to find a genetic cause.

13 Dec 2011

Basque engineer develops computer-based psychological tool for sportsperson

Teskal is a computing application designed to relieve 'the loneliness of the sportsperson'. The better a sportsperson is, the more time he or she spends away from home, and few can afford the luxury of travelling with psychologists, coaches, etc.

13 Dec 2011

Ruxolinitib reduces spleen size by 35% in patients with myelofibrosis

In a major advance in treatment, a multicenter study found that ruxolinitib did a better job than off-label chemotherapy drugs reducing the terrible symptoms associated with myelofibrosis, including pain, enlarged spleen, anemia, fever, chills, fatigue, and weight loss.

13 Dec 2011

S*BIO announces results from pacritinib Phase 2 study on myelofibrosis

S*BIO Pte Ltd today announced that results from a Phase 2 study demonstrated that its JAK2 inhibitor pacritinib (SB1518) effectively reduced splenomegaly in myelofibrosis (MF) patients, with minimal impact on existing cytopenias providing an important therapeutic niche in the treatment of MF. Results were presented at the 53rd ASH Annual Meeting and Exposition in San Diego.

13 Dec 2011

Combination of bortezomib and panobinostat shows promise against advanced MM

When the targeted drug bortezomib stops working in patients with advanced multiple myeloma, the patients survive only an average of five months longer. But a phase 2 clinical trial has shown that pairing bortezomib with an experimental drug, panobinostat, may be a promising new treatment for such patients, Dana-Farber Cancer Institute researchers say.

13 Dec 2011